BGB-15025

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Non-Small Cell Lung CancerAdvanced Malignancies

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

1

Nano-Crystalline Megestrol Acetate

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3

12

Carboplatin/paclitaxel

AstraZeneca

Phase 3

33

Consolidative Therapy

SSun Yat-sen University

Phase 3

24

BGB-15025

BeiGene

Phase 3

25

Remeron

OOrganon and Co

Preclinical

16

Treatment

GSK

Preclinical

17

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

18

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—9

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—10

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—Show 27 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer

Completed·BeiGene·Phase 2·NCT06029127·35 enrolled

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Active, not recruiting·BeiGene·Phase 2·NCT05635708·400 enrolled

Advanced Malignancies1 trial

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Enrolling by invitation·BBeOne Medicines·Phase 3·NCT04164199·430 enrolled

Advanced Solid Tumor1 trial

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Completed·BeiGene·Phase 1·NCT04649385·157 enrolled

Details

Drug Info

Related News